Natixis Advisors LLC Makes New $341,000 Investment in The Chemours Company (NYSE:CC)

Key Points

• Natixis Advisors LLC has acquired a new stake in The Chemours Company, purchasing 25,169 shares valued at around $341,000 during the 1st quarter.
• Analyst ratings are mixed, with UBS lowering its price target from $18.00 to $17.00 and Goldman Sachs reducing its target from $21.00 to $14.00, while Chemours has a consensus rating of "Hold" at an average price target of $17.38.
• The company recently reported earnings of $0.58 per share, surpassing expectations and showing a 5% increase in quarterly revenue compared to the previous year.

Natixis Advisors LLC acquired a new position in The Chemours Company (NYSE:CC - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 25,169 shares of the specialty chemicals company's stock, valued at approximately $341,000.

A number of other hedge funds have also recently added to or reduced their stakes in the business. FNY Investment Advisers LLC acquired a new position in shares of Chemours during the first quarter valued at $27,000. UMB Bank n.a. boosted its holdings in shares of Chemours by 73.9% during the first quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock valued at $30,000 after acquiring an additional 948 shares during the period. Farther Finance Advisors LLC boosted its holdings in shares of Chemours by 170.7% during the first quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company's stock valued at $30,000 after acquiring an additional 1,444 shares during the period. Itau Unibanco Holding S.A. increased its stake in shares of Chemours by 39.3% in the fourth quarter. Itau Unibanco Holding S.A. now owns 3,554 shares of the specialty chemicals company's stock valued at $60,000 after purchasing an additional 1,003 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Chemours during the fourth quarter valued at approximately $91,000. Institutional investors and hedge funds own 76.26% of the company's stock.

Chemours Price Performance

NYSE:CC traded down $0.48 during midday trading on Friday, hitting $14.59. 4,347,227 shares of the stock were exchanged, compared to its average volume of 4,548,641. The Chemours Company has a one year low of $9.13 and a one year high of $22.38. The company has a market capitalization of $2.18 billion, a price-to-earnings ratio of -5.21 and a beta of 1.61. The business has a 50-day moving average price of $12.57 and a two-hundred day moving average price of $13.06. The company has a current ratio of 1.68, a quick ratio of 0.83 and a debt-to-equity ratio of 17.16.

Chemours (NYSE:CC - Get Free Report) last announced its earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 EPS for the quarter, topping the consensus estimate of $0.46 by $0.12. Chemours had a positive return on equity of 35.14% and a negative net margin of 7.19%. The firm had revenue of $1.62 billion for the quarter, compared to analysts' expectations of $1.57 billion. During the same quarter in the previous year, the company earned $0.38 earnings per share. The firm's quarterly revenue was up 5.0% compared to the same quarter last year. Sell-side analysts predict that The Chemours Company will post 2.03 EPS for the current year.

Chemours Cuts Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, September 12th. Investors of record on Friday, August 15th will be issued a dividend of $0.0875 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $0.35 annualized dividend and a yield of 2.4%. Chemours's payout ratio is presently -12.50%.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on CC. UBS Group cut their price target on Chemours from $18.00 to $17.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Royal Bank Of Canada lifted their price target on Chemours from $14.00 to $15.00 and gave the company an "outperform" rating in a report on Thursday, July 3rd. Wall Street Zen cut Chemours from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. Barclays cut their price target on Chemours from $16.00 to $13.00 and set an "equal weight" rating on the stock in a report on Wednesday, May 28th. Finally, Mizuho lifted their price target on Chemours from $13.00 to $16.00 and gave the company an "outperform" rating in a report on Tuesday, July 15th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $17.38.

Insider Buying and Selling

In other Chemours news, CEO Denise Dignam purchased 4,068 shares of the firm's stock in a transaction on Friday, August 8th. The shares were purchased at an average price of $12.06 per share, for a total transaction of $49,060.08. Following the completion of the transaction, the chief executive officer owned 191,546 shares in the company, valued at $2,310,044.76. This represents a 2.17% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Shane Hostetter purchased 4,450 shares of the firm's stock in a transaction on Monday, May 19th. The stock was acquired at an average price of $11.28 per share, for a total transaction of $50,196.00. Following the transaction, the chief financial officer owned 59,694 shares of the company's stock, valued at $673,348.32. The trade was a 8.06% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 29,740 shares of company stock valued at $300,633 over the last quarter. Corporate insiders own 0.47% of the company's stock.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.